Omav confirmed a favorable safety and tolerability profile in adult patients with FRDA in a real-world setting after 48 weeks of treatment. The sustained reduction in IL-6 levels further supports a potential direct immunomodulatory effect of the drug, consistent with its proposed disease-modifying activity. However, further long-term studies are warranted to better define the efficacy of Omav in FRDA.
Monday, October 12, 2026
Reduction of interleukin-6 levels in patients with Friedreich's Ataxia treated with omaveloxolone
Di Stefano V, Lima S, Campo S ... Reduction of interleukin-6 levels in patients with Friedreich's Ataxia treated with omaveloxolone; Journal of the Neurological Sciences, 2026; 491. DOI:10.1016/j.jns.2026.126204
